Inflammasome Therapeutics reported on Monday the receipt of the new second USD1.3m grant from the Bill & Melinda Gates Foundation to develop bioerodible implants for women, to provide prevention from HIV infection coupled with birth control.
In September 2020, the company received USD1.0m grant from the Bill & Melinda Gates Foundation for development of an 18-month sustained release bioerodible implant for birth control.
According to a Kaiser Family Foundation report, women represent 55% of all adults (15-49) living with HIV worldwide and HIV (along with complications related to pregnancy) is the leading cause of death among women of reproductive age.
The company said the 12-month bioerodible implant is expected to deliver a constant and consistent level of islatravir for HIV prevention and concurrently a consistent low plasma level of the hormone levonorgestrel. Once the drugs have been released in the body the implant will dissolve without a need for it to be removed, which is beneficial in areas of the world where it may be difficult to maintain follow-up.
Inflammasome Therapeutics is a private, science-based company that develops therapies for prevalent, degenerative diseases and sustained-release drug delivery systems
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results